Evenity (Romosozumab) Switching Protocols: From and To Other Osteoporosis Drugs

How Romosozumab Works: The Dual-Action Mechanism

Romosozumab blocks sclerostin, a protein secreted by osteocytes that normally suppresses bone formation and promotes osteoclast activity. Removing that brake simultaneously increases osteoblast activity and reduces osteoclast-driven resorption, producing a net anabolic effect seen with no other approved agent. The FDA label notes this dual effect sets romosozumab apart from both bisphosphonates and teriparatide. [1]

Sclerostin and the Wnt Pathway

Sclerostin binds to LRP5/6 co-receptors and antagonizes Wnt signaling in osteoblast precursors. Research published in the Journal of Bone and Mineral Research confirmed that circulating sclerostin levels are elevated in postmenopausal women and inversely correlated with bone formation markers. [2] Blocking sclerostin restores Wnt-driven osteoblast differentiation within weeks.

Bone Formation vs. Resorption Markers

In the phase 3 FRAME trial (N=7,180), romosozumab increased serum procollagen type 1 N-terminal propeptide (P1NP, a bone formation marker) by roughly 145% at one month. Bone resorption marker CTX fell approximately 55% over the same period, per NEJM 2016 data. [3] The combination of rising formation and falling resorption markers is unique among approved osteoporosis drugs and explains the rapid BMD gains seen in clinical practice.

Why the Effect Is Time-Limited

Sclerostin inhibition produces a transient anabolic window. By month 9 to 12, bone formation markers drift back toward baseline even with continued dosing, a phenomenon called "the anabolic window closing." This pharmacological reality, not arbitrary label design, is why the treatment course is capped at 12 monthly doses. Continuing beyond 12 months does not produce additional meaningful BMD gains and exposes patients to prolonged cardiovascular risk.

The ARCH Trial: Core Evidence for Sequencing Decisions

The ARCH trial (N=4,093) compared 12 months of romosozumab followed by alendronate versus alendronate alone for 24 months total in postmenopausal women with osteoporosis and prior fracture. At 24 months, romosozumab-to-alendronate reduced new vertebral fractures by 48% (P<0.001) and clinical fractures by 27% (P<0.001) compared with alendronate-to-alendronate. [4]

Hip Fracture Outcomes

Hip fracture reduction reached 38% in favor of the romosozumab-to-alendronate arm (P=0.02). [4] That magnitude of hip fracture reduction in a single 24-month window has not been replicated by any head-to-head bisphosphonate comparator trial published to date.

The Cardiovascular Signal in ARCH

ARCH also produced a cardiovascular safety signal that now defines prescribing practice. Serious cardiovascular adverse events occurred in 2.5% of the romosozumab arm versus 1.9% of the alendronate arm (P=0.07 for the overall trial; the finding drove the FDA boxed warning). [4] The Endocrine Society's 2019 clinical practice guideline explicitly states: "Romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year." [5]

FRAME vs. ARCH: Which Trial Informs Sequencing?

FRAME used placebo as a comparator and followed with denosumab; ARCH used alendronate as both comparator and follow-on therapy. For real-world sequencing decisions, ARCH is the more informative trial because it reflects the clinical question: is romosozumab-first superior to starting with a standard antiresorptive? The answer, for high-risk patients without recent cardiovascular events, is yes.

Switching TO Romosozumab: Prior-Therapy Considerations

Patients arriving at romosozumab have typically been on bisphosphonates, denosumab, or teriparatide/abaloparatide. Each scenario requires a different approach.

After Bisphosphonates

Switching from oral bisphosphonates (alendronate, risedronate) or intravenous zoledronic acid to romosozumab is the most common scenario and carries the fewest pharmacological concerns. Bisphosphonates suppress bone resorption by embedding in bone matrix; residual antiresorptive activity persists for months to years after discontinuation. A 2018 analysis in the Journal of Bone and Mineral Research found that prior bisphosphonate use attenuated the P1NP response to subsequent anabolic therapy by approximately 20-30%, though BMD gains remained clinically meaningful. [6]

Practical guidance: there is no mandatory washout period before starting romosozumab after an oral bisphosphonate. Romosozumab can begin at the next scheduled visit. After completing 12 doses, continuing the same bisphosphonate is a reasonable option, particularly for patients who tolerated alendronate before the switch.

After Denosumab

Switching from denosumab to romosozumab requires careful timing. Denosumab suppresses RANKL-driven osteoclast activity for approximately 6 months per dose. Stopping denosumab without immediate follow-on therapy causes rapid rebound bone loss, with vertebral fracture rates sharply elevated in the 12-18 months after discontinuation. The FREEDOM extension data published in Osteoporosis International demonstrated that BMD losses after denosumab discontinuation can negate years of gains within 12-24 months. [7]

If the goal is to transition from denosumab to romosozumab, the standard approach is to bridge the gap with a bisphosphonate first. Give zoledronic acid 5 mg IV approximately 6 months after the last denosumab dose, then start romosozumab 3-6 months later once bone turnover markers stabilize. Skipping the bisphosphonate bridge and going directly to romosozumab is not well-studied and risks vertebral fracture during the transition window.

After Teriparatide or Abaloparatide

Both teriparatide (Forteo) and abaloparatide (Tymlos) are PTH-related anabolic agents. Switching directly from PTH-based therapy to romosozumab is possible but typically not recommended as a first-line sequence. A 2019 study in the Journal of Clinical Endocrinology and Metabolism found that BMD gains from sequential anabolic therapy were inferior to anabolic-then-antiresorptive sequencing in most scenarios. [8] Romosozumab is generally reserved for patients who have not yet used a PTH-based agent or who have exhausted antiresorptive options, because the anabolic window should not be squandered on patients who have already used their "first anabolic slot."

Switching FROM Romosozumab: Mandatory Follow-On Therapy

This is the most clinically critical switching scenario. After completing 12 monthly doses of romosozumab, bone mineral density gains are substantial but completely reversible without follow-on antiresorptive therapy. The choice of follow-on agent determines how much of that benefit is preserved long-term.

Romosozumab to Denosumab

The FRAME trial sequence (romosozumab 210 mg monthly x 12 months, then denosumab 60 mg SC every 6 months) produced the highest sustained BMD gains of any published switching sequence. At 24 months post-romosozumab, lumbar spine BMD in the FRAME-extension arm on denosumab was 17.6% above baseline, per NEJM 2016 and its follow-on extension data. [3] Denosumab is preferred as follow-on when the patient has renal function precluding bisphosphonates (eGFR <35 mL/min/1.73m²) or prior GI intolerance to oral agents.

One practical concern: committing to denosumab as follow-on means committing to it indefinitely, because stopping denosumab itself then requires a bisphosphonate bridge. Counsel patients on this chain before starting.

Romosozumab to Bisphosphonate

ARCH demonstrated that 12 months of romosozumab followed by alendronate 70 mg weekly is effective and durable. At 36 months, the romosozumab-to-alendronate group maintained vertebral fracture risk reduction of 48% versus continued alendronate monotherapy. [4] Zoledronic acid 5 mg IV annually is a strong alternative for patients with adherence concerns, because a single annual infusion provides reliable antiresorptive coverage without the pill-taking burden.

The transition should be smooth in timing: administer the first bisphosphonate dose within 1-3 months of completing the final romosozumab injection. Delay beyond 6 months risks measurable BMD loss.

Romosozumab to Raloxifene or HRT

Raloxifene (Evista) and menopausal hormone therapy are weaker antiresorptive options. Neither has been studied as follow-on to romosozumab in a powered clinical trial. For patients who completed romosozumab and have absolute contraindications to bisphosphonates and denosumab (a rare clinical picture), raloxifene may be used, with the understanding that fracture risk reduction data supporting this sequence are absent.

Original Clinical Decision Framework: Matching the Right Follow-On Therapy

The table below synthesizes ARCH, FRAME, and renal-dosing guidelines to give clinicians a practical decision tree after romosozumab completion.

| Patient Profile | Preferred Follow-On | Alternative | Notes | |---|---|---|---| | No renal impairment, no GI issues | Alendronate 70 mg weekly | Zoledronic acid 5 mg IV yearly | ARCH-supported sequence | | eGFR <35, CKD-MBD stable | Denosumab 60 mg SC q6mo | Raloxifene (weaker evidence) | Avoid bisphosphonates; plan denosumab exit strategy | | Prior denosumab, stable now | Zoledronic acid 5 mg IV | Alendronate if tolerated | Bridge rebound risk before and after romo course | | Elevated cardiovascular risk (recent MI/stroke <12 months) | Do NOT start romosozumab | Use teriparatide or antiresorptive | FDA boxed warning applies | | Perimenopausal, low-trauma fracture, BMI <27 | Alendronate 70 mg weekly | HRT discussion warranted | Shared decision-making on HRT for bone + vasomotor symptoms |

This framework is not a substitute for individualized clinical judgment. Prescribers should review the full FDA label and the Endocrine Society 2019 guidelines before initiating or sequencing therapy.

Practical Administration and Monitoring

Romosozumab is given as two separate 105 mg/1.17 mL subcutaneous injections at each monthly visit, for a combined dose of 210 mg. Injections should be administered by a healthcare professional, though self-injection at home is permitted after training. The FDA label specifies administration into the abdomen, thigh, or upper arm, rotating sites between the two injections. [1]

Laboratory Monitoring Before and During Treatment

Correct hypocalcemia before the first dose. Check serum calcium, vitamin D (25-OH), and basic metabolic panel at baseline. For patients with severe vitamin D deficiency (25-OH <20 ng/mL), replete to >30 ng/mL before starting. The National Osteoporosis Foundation recommends 1,000-1,200 mg calcium daily and 800-1,000 IU vitamin D daily for patients on bone-active therapies. [9]

Monitor bone turnover markers (P1NP, CTX) at 3 and 6 months to confirm a formation response. Absence of a P1NP rise by month 3 may indicate prior heavy bisphosphonate suppression and warrants reassessment.

DXA Timing

Baseline DXA of lumbar spine, total hip, and femoral neck should be obtained before starting. Repeat DXA at 12 months (end of romosozumab course) and again at 24 months on the follow-on agent. T-score improvement targets for treatment response are not universally defined, but a lumbar spine BMD increase of >3% above the least significant change threshold at 12 months is generally considered a favorable response.

Cardiovascular Risk: Patient Selection Is Everything

The boxed warning on romosozumab is not a theoretical concern. ARCH recorded a numerically higher rate of serious cardiovascular events (heart attack, stroke, cardiovascular death) with romosozumab versus alendronate: 50 events (2.5%) vs. 38 events (1.9%). [4] The FDA determined this difference warranted a boxed warning, the agency's strongest safety label designation.

The American Heart Association advises clinicians to perform a formal cardiovascular risk assessment using validated tools such as the Framingham Risk Score or the Pooled Cohort Equations before prescribing any medication associated with cardiovascular adverse events. [10]

For patients with a 10-year cardiovascular risk below 10% and no history of MI or stroke, the fracture risk reduction of romosozumab generally outweighs the cardiovascular signal, particularly for those with T-score <-3.0 or prior low-trauma vertebral fracture. For patients with recent cardiovascular events or established coronary artery disease, teriparatide (Forteo) 20 mcg SC daily for up to 24 months is the preferred anabolic alternative.

Special Populations

Men With Osteoporosis

Romosozumab is FDA-approved only for postmenopausal women. Male osteoporosis data are limited. A phase 3 trial in men (BRIDGE, NCT02186171) showed BMD gains comparable to female trials, but the drug does not carry FDA approval for men, and off-label use requires individualized risk-benefit discussion. Results from the BRIDGE study were published in the Journal of Bone and Mineral Research in 2019. [11]

Glucocorticoid-Induced Osteoporosis

Glucocorticoid-induced osteoporosis (GIOP) is driven by direct osteoblast suppression. Romosozumab's anabolic mechanism is theoretically well-suited to GIOP, but no large randomized controlled trial has been completed in this population. The ACR 2022 GIOP guideline conditionally recommends teriparatide or zoledronic acid as first-line for high-risk GIOP; romosozumab is not yet positioned in these guidelines as a standard option for this indication. See the ACR GIOP guideline at pubmed.ncbi.nlm.nih.gov for current recommendations. [12]

Romosozumab vs. Teriparatide: Head-to-Head Comparison

No randomized trial has directly compared romosozumab and teriparatide head-to-head with fracture outcomes as the primary endpoint. BMD comparisons exist: a 12-month trial published in NEJM 2016 (N=436) showed romosozumab produced significantly greater lumbar spine BMD gains (13.7%) versus teriparatide (9.8%) over 12 months (P<0.001). [3]

Clinically, the choice between the two agents often comes down to cardiovascular history (favor teriparatide if present), prior bisphosphonate exposure (attenuates teriparatide more than romosozumab), and follow-on therapy planning. Both agents require antiresorptive follow-on. Both have a finite treatment duration (24 months for teriparatide; 12 months for romosozumab).